Your browser doesn't support javascript.
loading
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell, Dean A; Ewings, Sean; Ottensmeier, Christian; Califano, Raffaele; Hanna, Gerard G; Hill, Kayleigh; Danson, Sarah; Steele, Nicola; Nye, Mavis; Johnson, Lucy; Lord, Joanne; Middleton, Calley; Szlosarek, Peter; Chan, Sam; Gaba, Aarti; Darlison, Liz; Wells-Jordan, Peter; Richards, Cathy; Poile, Charlotte; Lester, Jason F; Griffiths, Gareth.
Afiliação
  • Fennell DA; Mesothelioma Research Programme, Leicester Cancer Research Centre, University of Leicester, Leicester, UK; University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address: df132@le.ac.uk.
  • Ewings S; Cancer Research UK, Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Ottensmeier C; Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Califano R; Department of Medical Oncology, Wythenshaw Hospital, Manchester, UK.
  • Hanna GG; Peter MacCullum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Hill K; Cancer Research UK, Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Danson S; Department of Radiation Oncology, University of Sheffield, Sheffield, UK.
  • Steele N; Department of Oncology and Metabolism University of Glasgow, Glasgow, UK.
  • Nye M; Mavis Nye Foundation, University of Southampton, Southampton, UK.
  • Johnson L; Cancer Research UK, Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Lord J; Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK.
  • Middleton C; Cancer Research UK, Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Szlosarek P; Cancer Research UK Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Chan S; York Teaching Hospital NHS Foundation Trust, York, UK.
  • Gaba A; Mesothelioma Research Programme, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Darlison L; University Hospitals of Leicester NHS Trust, Leicester, UK; Department of Oncology, Mesothelioma UK, Leicester, UK.
  • Wells-Jordan P; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Richards C; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Poile C; Mesothelioma Research Programme, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Lester JF; The Rutherford Cancer Centre, Newport, UK.
  • Griffiths G; Cancer Research UK, Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Lancet Oncol ; 22(11): 1530-1540, 2021 11.
Article em En | MEDLINE | ID: mdl-34656227
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Nivolumabe / Inibidores de Checkpoint Imunológico / Mesotelioma Maligno Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Nivolumabe / Inibidores de Checkpoint Imunológico / Mesotelioma Maligno Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido